- Home
- ACLX vs ADMA Comparison
ACLX vs ADMA Comparison
Compare ACLX & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACLX | ADMA |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACLX | ADMA |
|---|---|---|
| Price | $64.69 | $19.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $115.71 | $28.50 |
| AVG Volume (30 Days) | 1.6M | ★ 3.0M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 205.35 |
| EPS | N/A | ★ 0.86 |
| Revenue | $35,898,000.00 | ★ $488,559,000.00 |
| Revenue This Year | N/A | $22.19 |
| Revenue Next Year | $302.49 | $24.33 |
| P/E Ratio | ★ N/A | $22.87 |
| Revenue Growth | N/A | ★ 27.63 |
| 52 Week Low | $47.86 | $13.50 |
| 52 Week High | $94.07 | $25.67 |
Technical Indicators
Market Signals| Indicator | ACLX | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 31.97 | 61.00 |
| Support Level | $68.64 | $18.33 |
| Resistance Level | $73.98 | $20.46 |
| Average True Range (ATR) | 4.47 | 0.73 |
| MACD | -0.47 | -0.19 |
| Stochastic Oscillator | 6.21 | 58.74 |
Price Performance
Historical ComparisonAbout ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.